Peptides and pharmaceutical compositions comprising same

Details Peptides and pharmaceutical compositions comprising same Peptides and pharmaceutical compositions comprising same

2007-03-27

2007-03-27

Chism, B. Dell (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S012200, C514S015800, C514S016700, C424S001690, C424S009100

Reexamination Certificate

active

10048955

ABSTRACT:
The present invention relates to an NST500 compound of general formula (I): comprising the following components: X1—X2—{(X3)a/X4/X5}—X6, wherein: X1stands for a saturated or unsaturated fatty acid residue comprising 6–20 carbon atoms; or a cysteine residue bound through a thioether bond to a prenyl group comprising 5–20 carbon atoms; said residue being linked to the adjacent component of the compound through an amide bond; X2is 0; X3comprises 1–6 amino acids, of which 1–6 are positively charged and 0–2 are negatively charged, the other amino acid residues being polar uncharged amino acids; X4comprises 1–6 amino acids, of which 1–2 are aromatic amino acids, the other amino acids being selected among polar uncharged amino acids and hydrophobic aliphatic amino acids; X5comprises 6–8 amino acids, of which 4–6 are positively charged and 0–2 are negatively charged, the other amino acid residues being polar uncharged amino acids, wherein the amino acids form a cyclic structure; X6is a compound of general formula II, wherein Z stands for a spacer group selected among alkane and alkene containing 1–5 carbon atoms, J stands for a functional group selected among amines, thiols, alcohols, carboxylic acids and esters, aldehydes and alkyl halides; U is 0 or is selected among a labeling group; wherein a stands for an integer of 1–3; and the groups X3, X4and X5being located at various places in the compound; as well as functional equivalents thereof and/or compounds having the same biological activity thereto. The present also relates to pharmaceutical compositions and methods of using the same.

REFERENCES:
patent: 3701433 (1972-10-01), Krakauer et al.
patent: 3935111 (1976-01-01), Bentley
patent: 4283289 (1981-08-01), Meyst et al.
patent: 4350594 (1982-09-01), Kawai et al.
patent: 4572724 (1986-02-01), Rosenberg et al.
patent: 5552290 (1996-09-01), Michelson et al.
patent: 5567615 (1996-10-01), Degen et al.
patent: 5608060 (1997-03-01), Axworthy et al.
patent: 5630946 (1997-05-01), Hart et al.
patent: 5630996 (1997-05-01), Reno et al.
patent: 5744047 (1998-04-01), Gsell et al.
patent: 5834433 (1998-11-01), Krstenansky
patent: 5910442 (1999-06-01), Gelman
patent: 6024964 (2000-02-01), Jung et al.
patent: 6074650 (2000-06-01), Jung et al.
patent: 0 210 412 (1987-02-01), None
patent: 0 755 516 (1997-01-01), None
patent: 125908 (1998-08-01), None
patent: WO 91/04628 (1991-04-01), None
patent: WO 95/34315 (1995-12-01), None
patent: WO 96/29403 (1996-09-01), None
patent: WO 97/01760 (1997-01-01), None
patent: WO 97/35971 (1997-10-01), None
patent: WO 97/40059 (1997-10-01), None
patent: WO 97/40070 (1997-10-01), None
patent: WO 98/05777 (1998-02-01), None
patent: WO 00/10673 (2000-03-01), None
patent: WO 01/18031 (2001-03-01), None
Halbreich et al., “Biomedical Applications of Maghemite Ferrofluid”, May-Jun. 1998, pp. 379-390, Biochimie, 80(5-6).
Mercy Joseph et al., “Conformations of Peptides Corresponding to Fatty Acylation Sites in Proteins”, pp. 19439-19440, Aug. 18, 1995, The Journal of Biological Chemistry, vol. 270, No. 33.
Miltenyi Biotec Inc. “MACS Apoptotic Cell Isolation Kit”,,,251 Suburn Ravine Rd., Suite 208, Auburn CA 95603, Brochure.
Moumaris et al., “Effect of Fatty Acid Treatment in Cerebral Malaria-Susceptible and Nonsusceptible Strains of Mice”, Dec. 1995, pp. 997-999, J. Parasitol, 81 (6).
Muchmore et al., “X-Ray and NMR Structure of Human BCL-X, an Inhibitor of Programmed Cell Death”, May 23, 1996, pp. 335-341, Letters to Nature, vol. 381.
Sabolovic et al., “Membrane Modifications of Red Blood Cells in Alzheimer's Disease”, Jul. 1997, pp. 217-220, J. Gerontol. A. Biol. Sci. Med. Sci., 52(4):B.
Sestier et al., “Use of Annexin V-Ferrofluid to Enumerate Erythrocytes Damaged in Varouis Pathologies or During Storage In Vitro”, Nov. 1995, pp. 1141-1146, C R Acad Sci III, 318:11.

Affiliated with

Also associated with

Rating

Peptides and pharmaceutical compositions comprising same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides and pharmaceutical compositions comprising same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and pharmaceutical compositions comprising same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3740853